AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Form 3 of AZD5718 tabletsDrug: Form 4 of AZD5718 tabletsDrug: Form 2 of AZD5718 tabletsDrug: Selected form (Form 2 - 5) of AZD5718 tabletsDrug: Form 5 of AZD5718 tabletsDrug: Form 1 of AZD5718 tablets
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT03420092
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: TezepelumabOther: Placebo
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT03406078
- Locations
- 🇺🇦
Research Site, Vinnytsia, Ukraine
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 279
- Registration Number
- NCT03402841
- Locations
- 🇬🇧
Research Site, Scarborough, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men
Phase 1
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: AZD5718 oral suspensionOther: Placebo matching AZD5817 oral suspension
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT03400488
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
Phase 3
Completed
- Conditions
- Nasal Polyposis
- Interventions
- Biological: Benralizumab 30 mg SC + Mometasone FuroateBiological: Matching placebo SC + Mometasone Furoate
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT03401229
- Locations
- 🇵🇱
Research Site, Łódź, Poland
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT03394144
- Locations
- 🇯🇵
Research Site, Matsuyama-shi, Japan
Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 253
- Registration Number
- NCT03387722
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT03387683
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Long-term Observational Study of the Safety of Roflumilast
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 135856
- Registration Number
- NCT03381573
- Locations
- 🇸🇪
Research Site, Solna, Sweden
A Study to Evaluate the Symptoms Over 24 Hours in Patients With Chronic Obstructive Pulmonary Disease - LASSYC Study
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 602
- Registration Number
- NCT03381560
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
© Copyright 2025. All Rights Reserved by MedPath